Page 1 - reflections_dyslipidaemia_newsletter9_Final
P. 1
REFLECTIONS
Dyslipidaemia
Dyslipidaemia Global Newsletter #9 2025
TABLE OF CONTENTS
KEY ARTICLES Welcome back to the Reflections Dyslipidaemia Global Newsletter,
where an international Scientific Planning Committee summarises
GUIDELINES AND DIAGNOSTICS and provides expert commentary on the latest clinical and real-
AHA PREVENT equations and lipoprotein(a) for world evidence in the field of dyslipidaemia. These articles are
cardiovascular disease risk: Insights from MESA and chosen based on their significance to everyday clinical practice.
Dyslipida
the UK Biobank. Bhatia HS, et al. JAMA Cardiol. 2025 Jun 4: This newsletter features insights into cardiovascular disease
e251603. doi: 0.1001/jamacardio.2025.1603. Online ahead of print.
risk assessment, including the performance of the new AHA
Clinical staging to guide management of metabolic PREVENT equations with Lp(a) and the appropriate use of CAC
disorders and their sequelae: A European Atherosclerosis
Society consensus statement Romeo S, et al. Eur Heart J. testing, highlights the EAS consensus on clinical staging for
2025 May 7:ehaf314. doi: 10.1093/eurheartj/ehaf314. Online ahead systemic metabolic disorders, explores novel triglyceride-lowering
of print. therapies for acute pancreatitis, ASCVD, and MASH, and reviews
Coronary artery calcium testing-too early, too late, too a clinical consensus on managing hypercholesterolaemia in
often. Zheutlin AR, et al. JAMA Cardiol. 2025;10(5):503-509. adults over 75 years without established ASCVD. As with previous
newsletters, we invite you to interact through links to short video
TREATMENT commentaries from our SPC, links to videos or podcasts, along
Early ezetimibe initiation after myocardial infarction with hyperlinks to full articles for in-depth study and reflection.
protects against later cardiovascular outcomes in the
SWEDEHEART registry. Leosdottir M, et al. J Am Coll Cardiol. Prof. Farnier (Chair)
2025;85(15):1550-1564.
Target populations for novel triglyceride-lowering SCIENTIFIC PLANNING COMMITTEE
therapies. Nordestgaard AT, et al. J Am Coll Cardiol.
2025;85(19):1876-1897.
Prof. Michel Farnier Prof. Choong Hou Koh
SPECIAL POPULATIONS – (France) (Singapore)
HYPERCHOLESTEROLEMIA IN ELDERLY
Managing hypercholesterolemia in adults older than 75
years without a history of atherosclerotic cardiovascular Prof. Augusto Lavalle Prof. Ahmed Shawky
disease: An Expert Clinical Consensus from the National Cobo (Egypt)
Lipid Association and the American Geriatrics Society. (Argentina)
Bittner V, et al. J Clin Lipidol. 2025;19(2):215-237.
Prof. Cristina Gavina Prof. Marcin Welnicki
ADDITIONAL ARTICLES OF INTEREST (Portugal) (Poland)
GUIDELINES AND DIAGNOSTICS
AHA PREVENT equations and lipoprotein(a) for cardiovascular disease risk:
Insights from MESA and the UK Biobank.
Bhatia HS, et al. JAMA Cardiol. 2025 Jun 4: e251603. doi: 0.1001/jamacardio.2025.1603. Online ahead of print.
Lipoprotein(a) (Lp[a]) is a LDL-like lipoprotein that is genetically determined and independently associated with ASCVD, aortic
valvular disease, and heart failure (HF). Despite its association with ASCVD risk, Lp(a) is not included in the American Heart
Association (AHA) Predicting Risk of Cardiovascular Disease Events (PREVENT) equations, which were developed to replace the
older pooled cohort equations (PCEs) for ASCVD risk prediction. Given the potential use of PREVENT equations for risk prediction in
upcoming guidelines, this study evaluates the performance of the PREVENT risk scores in individuals with elevated Lp(a).
The cohort study involved 314,783 participants from two large multiethnic populations: the Multi-Ethnic Study of Atherosclerosis
(MESA, 2000–2018) and the UK Biobank (UKB, 2006–2022), all without known cardiovascular disease but with available Lp(a)
